Ipsen’s FOP saga continues as FDA postpones Oct. 31 adcom FDA/Regulatory, R&D Ipsen’s fibrodysplasia ossificans progressiva (FOP) odyssey continues as the FDA’s Endocrinologic and Metabolic Drugs Advisory Committee postponed its meeting on the NDA for palovarotene capsules. Read more October 25, 2022/by BioSpace https://www.pharmalive.com/wp-content/uploads/2021/11/FDA-COVID-19-Vaccine-Boosters-for-All-18-Plus-BioSpace-11-19-21.jpeg 350 625 BioSpace https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png BioSpace2022-10-25 17:00:282022-10-26 11:47:52Ipsen's FOP saga continues as FDA postpones Oct. 31 adcom
